RBC keeps Medicines Co. at sector perform

RBC Capital Markets analyst Jason Kantor reiterated The Medicines Co. at sector perform, above average risk, ahead of the company's third-quarter results. RBC lowered is third-quarter Angiomax U.S. estimate to $54 million from $55 million to reflect seasonal weakness. Angiomax is a superior anticoagulant in the cath lab setting, and sales are expected to pick up in the fourth quarter, according to Kantor. Shares of the Parsippany, N.J.-based pharmaceutical company were down 61 cents, or 2.62%, at $22.65. (Nasdaq: MDCO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.